LONDON - The European Commission has authorized the use of Vocabria and Rekambys, a long-acting injectable regimen, for adolescents living with HIV-1, ViiV Healthcare, majority-owned by GSK (NYSE: GSK ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Vocabria (cabotegravir ...

The FTSE 100 index has started the year well as it surged to a record high. It moved to a high of £8,645, up by over 75% from ...

Two innovative projects in Nigeria and Ethiopia have received significant funding from Save the Children through its Immunisation Accelerator, supported by ...

The 30th Nigerian Economic Summit (#NES30) was held in Abuja on October 14, 2024. At that summit, the Vice President of the ...

Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...

Pharmaceutical giant GSK and the University of Oxford are collaborating on developing a cancer vaccine that aims to detect pre-cancer cells up to 20 y ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio. The expansion is fueled by increased ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...